A randomized, double-blind, placebo-controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 162 [denosumab] in the treatment of postmenopausal women with low bone mineral density.

Trial Profile

A randomized, double-blind, placebo-controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 162 [denosumab] in the treatment of postmenopausal women with low bone mineral density.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Denosumab (Primary) ; Alendronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 01 Jan 2013 Results at 8 years published in Osteoporosis International.
    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 20 Sep 2011 Eight-year results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top